Pfizer and BioNTech have said trial results show their COVID-19 vaccine is safe and produces a robust immune response in children aged five to 11, adding that they would seek regulatory approval shortly.The vaccine would be administered at a lower dosage than for people aged above 12, US pharma giant Pfizer and its German partner said in a joint statement.“In participants five to 11 years of age, the vaccine was safe, well tolerated and showed robust neutralising antibody responses,” the statement said.
Load More
Load More